RYTM — Rhythm Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $7.58bn
- $7.27bn
- $130.13m
- 77
- 10
- 73
- 53
Annual income statement for Rhythm Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 3.15 | 23.6 | 77.4 | 130 |
| Cost of Revenue | |||||
| Gross Profit | — | 2.56 | 21.5 | 68.1 | 117 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 137 | 173 | 203 | 262 | 396 |
| Operating Profit | -137 | -170 | -179 | -184 | -266 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -134 | -69.6 | -181 | -184 | -260 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -134 | -69.6 | -181 | -185 | -261 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -134 | -69.6 | -181 | -185 | -261 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -134 | -69.6 | -181 | -185 | -265 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.04 | -1.4 | -3.47 | -3.2 | -4.34 |